These findings are relevant to our understanding of the role of the 4E-BPs in regulating the malignant phenotype, as well as the therapeutic responses to mTOR inhibitors of tumour cells with deregulated PI3-kinase, Akt or mTOR activity. This evidence concerns the gene AKT1 and neoplasm.